KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to -$10.0 million.

  • Abbott Laboratories' Exchange Rate Effect fell 12777.78% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.0 million, marking a year-over-year decrease of 25000.0%. This contributed to the annual value of -$96.0 million for FY2024, which is 31739.13% down from last year.
  • Abbott Laboratories' Exchange Rate Effect amounted to -$10.0 million in Q3 2025, which was down 12777.78% from $51.0 million recorded in Q2 2025.
  • Abbott Laboratories' Exchange Rate Effect's 5-year high stood at $51.0 million during Q4 2022, with a 5-year trough of -$96.0 million in Q3 2022.
  • Its 5-year average for Exchange Rate Effect is -$12.9 million, with a median of -$13.0 million in 2021.
  • Within the past 5 years, the most significant YoY rise in Abbott Laboratories' Exchange Rate Effect was 49230.77% (2022), while the steepest drop was 187500.0% (2022).
  • Quarter analysis of 5 years shows Abbott Laboratories' Exchange Rate Effect stood at -$13.0 million in 2021, then soared by 492.31% to $51.0 million in 2022, then plummeted by 50.98% to $25.0 million in 2023, then crashed by 432.0% to -$83.0 million in 2024, then skyrocketed by 87.95% to -$10.0 million in 2025.
  • Its Exchange Rate Effect stands at -$10.0 million for Q3 2025, versus $51.0 million for Q2 2025 and $24.0 million for Q1 2025.